A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Exclusion Criteria

• •Active drug or alcohol abuse.
• •Co-existing Condition:
• •Patients with the following complications are excluded:
• •Active opportunistic infections requiring ongoing therapy.
• •Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study.
• •Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
• •Concurrent neoplasms other than basal cell carcinoma of skin.
• •Known sensitivity to polymycin or neomycin.
• •Patients with the following complications are excluded:
• •Active opportunistic infections requiring ongoing therapy.
• •Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study.
• •Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia.
• •Concurrent neoplasms other than basal cell carcinoma of skin.
• •Known sensitivity to polymycin or neomycin.
• •Prior Medication:
• •Excluded:
• •Any prior zidovudine (AZT) or interferon alpha protocol participation.
• •Excluded within 30 days of study entry:
• •Immunomodulating agents.
• •Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives.
• •Excluded within 90 days of study entry:
• •Antiretroviral agents.
• •Treatment of Pneumocystis carinii pneumonia (PCP).
• •Prior Treatment:
• •Excluded within 30 days of study entry:
• •Radiation therapy.